Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Background Information:
MGCD516 is a clinical stage, orally available and potent small molecule inhibitor, targeting a closely related family of Receptor Tyrosine Kinases (RTKs) including RET, TRK, DDR2, MET, Axl , KIT, as well as VEGFR and PDGFR family members. RTKs inhibited by MGCD516 are genetically altered in a variety of cancers, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), functioning as oncogenic drivers promoting cancer development and progression. Alterations in these RTKs have also been implicated in tumor resistance mechanisms. MGCD516 has demonstrated broad antitumor activity including demonstration of tumor regression in preclinical models harboring genetic dysregulation of MGCD516 targets including MET amplification, METex14del, RET rearrangement and CHR4q12 amplification. It is currently in clinical evaluations.
APIM050197: MGCD516 (SITRAVATINIB)
CAS No.: 1123837-84-2.
Molecular Formula: C33H29F2N5O4S? 0.3H2O.
Molecular Weight: 635.1.
Purity: >98.5% by HPLC.
QC: HPLC-MS, 1HNMR, and Quantitative Elemental Analysis.
Solubility: Soluble in DMSO.
Storage: Store at 0-4 °C (short term), -20 °C (long term), desiccated.
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf